Synergen Inc. has agreed to reacquire European commercialrights to its Trofak human basic fibroblast growth factor fromZyma S.A. of Nyon, Switzerland.

"Zyma hadn't begun clinical trials in Europe and had investedonly $1 million to $1.5 million in Trofak" to develop topicalapplications, said Synergen spokeswoman Debra Bannister.Also, Trofak did not fit into Ciba-Geigy Ltd.'s strategy forZyma, she said. Ciba-Geigy completed its acquisition of Zymain May.

Boulder, Colo.-based Synergen has also changed its strategy,aiming to keep full rights to its products in Europe. Thecompany (NASDAQ:SYGN) approached Zyma, which agreed togive up Trofak. In exchange, Zyma "doesn't have to put any moremoney into Trofak," Bannister said. No significant amount ofmoney is changing hands.

Trofak is in Phase III clinical trials in the United States totreat chronic skin ulcers. -- KB

(c) 1997 American Health Consultants. All rights reserved.